Prophylactic Treatment With Oseltamivir

University Medical Centre Ljubljana222 enrolled

Overview

The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

222

Conditions

Influenza, Human

Interventions

Oseltamivir Oral Capsule for 5 days post-exposureDRUG

Patients will receive oseltamivir for 5 days after last influenza exposure.

Oseltamivir Oral Capsule for 10 days post-exposureDRUG

Patients will receive oseltamivir for 10 days after last influenza exposure.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older * exposure to influenza during hospitalization * risk factors for influenza complications * consent for participation obtained Exclusion Criteria: * younger than 18 years * hematological malignancy * hospitalized in intensive care unit * refusal to participate

Locations (1)

University Medical center Ljubljana

Ljubljana, Slovenia

Outcomes

Primary Outcomes

Occurrence of influenza like illness 10 days after oseltamivir prophylactic therapy

Experiencing influenza like illness as self assessed by a patient and/or as assessed by a medical doctor while on prophylaxis with oseltamivir and during the following 10 days.

Time frame: 10 days after oseltamivir prophylactic therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.